This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
May 20, 2021
Nordic Nanovector ASA: Invitation to First Quarter 2021 Results Presentation and Webcast
May 19, 2021
Oncopeptides presents clinical abstracts on melflufen at the 2021 American Society of Clinical Oncology
May 17, 2021
Zephyr® Valve Treatment Provides Long-Term Quality of Life and Lung Function Improvements for Patients with Severe COPD/Emphysema
May 13, 2021
Strongbridge Biopharma plc Announces U.S. Food & Drug Administration (FDA) Filing Acceptance of New Drug Application (NDA) for RECORLEV® (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome
May 12, 2021
Oncopeptides presents new clinical and preclinical melflufen data at the upcoming European Hematology Association meeting
May 12, 2021
Spruce Biosciences Reports First Quarter 2021 Financial Results And Provides Corporate Updates
May 12, 2021
Strongbridge Biopharma plc Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021
Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results And Business Update
May 06, 2021
Aprea Therapeutics Reports First Quarter 2021 Financial Results and Provides Update on Business Operations
May 06, 2021
Fusion Pharmaceuticals Announces Clinical Collaboration With Merck To Evaluate Fusion’s Targeted Alpha Therapy (TAT) In Combination With Merck’s KEYTRUDA® (Pembrolizumab) In Patients With Solid Tumors Expressing IGF-1R